



4D Molecular Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

June 3, 2021

EMERYVILLE, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8 at 2:30 p.m. PT.

A live audio webcast of the fireside chat will be available by visiting the "Investors & Media" section of the 4DMT website at www.4dmolecularterapeutics.com. A replay of the webcast will be available for at least two weeks following the live event.

About 4DMT

4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP patients, 4D-110 is in a Phase 1 clinical trial for choroideremia patients and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease patients.

4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT

Contacts:

Media:

Theresa Janke
tjanke@4dmt.com

Investors:

Mike Zaroni
Endurance Advisors
mzanoni@4dmt.com